Joseph Rubino

591 total citations
6 papers, 290 citations indexed

About

Joseph Rubino is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Joseph Rubino has authored 6 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Surgery, 3 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Joseph Rubino's work include Lipoproteins and Cardiovascular Health (3 papers), Pharmaceutical Economics and Policy (2 papers) and Hormonal Regulation and Hypertension (2 papers). Joseph Rubino is often cited by papers focused on Lipoproteins and Cardiovascular Health (3 papers), Pharmaceutical Economics and Policy (2 papers) and Hormonal Regulation and Hypertension (2 papers). Joseph Rubino collaborates with scholars based in United States, Canada and Australia. Joseph Rubino's co-authors include Harold Bays, Lawrence A. Leiter, Scott Conard, Joanne E. Tomassini, Steven Bird, Andrew M. Tershakovec, Mary E. Hanson, Robert S. Lowe, Michael H. Davidson and Eliot A. Brinton and has published in prestigious journals such as The American Journal of Cardiology, American Heart Journal and Clinical Therapeutics.

In The Last Decade

Joseph Rubino

6 papers receiving 284 citations

Peers

Joseph Rubino
Bei Wang China
Kévin Chemello France
Julia Brandts Germany
J. Lin United States
Mary Elliott‐Davey United States
S. J. Leslie United States
Kate Tsirtsonis United States
Laurent Kassalow United States
Claudia Morozzi Italy
Tomas Hala United States
Bei Wang China
Joseph Rubino
Citations per year, relative to Joseph Rubino Joseph Rubino (= 1×) peers Bei Wang

Countries citing papers authored by Joseph Rubino

Since Specialization
Citations

This map shows the geographic impact of Joseph Rubino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Rubino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Rubino more than expected).

Fields of papers citing papers by Joseph Rubino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Rubino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Rubino. The network helps show where Joseph Rubino may publish in the future.

Co-authorship network of co-authors of Joseph Rubino

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Rubino. A scholar is included among the top collaborators of Joseph Rubino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Rubino. Joseph Rubino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Anderson, Peter M., Stefan Bielack, Richard Görlick, et al.. (2016). A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer. 63(10). 1761–1770. 74 indexed citations
2.
Jones-Burton, Charlotte, Joseph Rubino, Sophie Roy, et al.. (2010). Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension. 4(5). 219–226. 6 indexed citations
3.
Cannon, Christopher P., Hayes M. Dansky, Michael H. Davidson, et al.. (2009). Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib. American Heart Journal. 158(4). 513–519.e3. 65 indexed citations
4.
Conard, Scott, Harold Bays, Lawrence A. Leiter, et al.. (2008). Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.. The American Journal of Cardiology. 102(11). 1489–1494. 62 indexed citations
5.
Leiter, Lawrence A., Harold Bays, Scott Conard, et al.. (2008). Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease. The American Journal of Cardiology. 102(11). 1495–1501. 71 indexed citations
6.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bei Wang Breakdown of academic impact, for papers by Kévin Chemello Breakdown of academic impact, for papers by Julia Brandts Breakdown of academic impact, for papers by J. Lin Breakdown of academic impact, for papers by Mary Elliott‐Davey Breakdown of academic impact, for papers by S. J. Leslie Breakdown of academic impact, for papers by Kate Tsirtsonis Breakdown of academic impact, for papers by Laurent Kassalow Breakdown of academic impact, for papers by Claudia Morozzi Breakdown of academic impact, for papers by Tomas Hala
Rankless by CCL
2026